Stenocide Injection

Introduction

Stenocide is a prescription medication that combines the active ingredients Ticarcillin and Clavulanic Acid. It is available under the brand name Stenocide. This medication is primarily used to treat bacterial infections in adults and children.

Uses

Stenocide is prescribed to treat a range of bacterial infections, including respiratory tract infections, skin and soft tissue infections, urinary tract infections, and intra-abdominal infections. Note that this medication is only effective against bacterial infections and will not treat viral infections, such as the common cold or flu.

Dosage and Administration

The dosage of Stenocide will vary depending on the severity of the infection and the individual patient. It is typically administered intravenously by a healthcare professional. The exact dosage and duration of treatment will be determined by your healthcare provider. Follow their instructions carefully and complete the full course of treatment, even if you start to feel better.

Mechanism of Action

Stenocide contains two active ingredients: Ticarcillin and Clavulanic Acid. Ticarcillin is an antibiotic that works by inhibiting the growth and reproduction of bacteria. Clavulanic Acid is a beta-lactamase inhibitor, which helps to prevent the breakdown of Ticarcillin by certain bacteria that would otherwise render it ineffective. Together, these ingredients work synergistically to effectively treat bacterial infections.

Side Effects

Common side effects may include diarrhea, nausea, vomiting, rash, and itching. If any of these side effects persist or worsen, notify your healthcare provider.

In rare cases, Stenocide may cause more serious side effects, such as severe allergic reactions, including difficulty breathing, swelling of the face or throat, or hives. If you experience any of these symptoms, seek immediate medical attention.

Drug Interactions

inform your healthcare provider about all the medications you are currently taking, including prescription and over-the-counter medications, as well as any herbal supplements. Stenocide may interact with certain medications, such as anticoagulants, methotrexate, and probenecid. These interactions can affect the effectiveness of the medication or increase the risk of side effects. Your healthcare provider will carefully consider these interactions when prescribing Stenocide.

Precautions

Before using Stenocide, inform your healthcare provider about any allergies you may have, especially to penicillin or cephalosporin antibiotics. Additionally, let your healthcare provider know about any medical conditions you have, such as kidney disease or liver disease, as these may affect the use of this medication.

Stenocide may also interact with certain substances, such as alcohol. Avoid consuming alcohol while using this medication, as it may increase the risk of side effects.

Storage

Patient Tips

• Follow the instructions provided by your healthcare provider for the administration of Stenocide.
• Complete the full course of treatment, even if you start to feel better.
• If you miss a dose, contact your healthcare provider for further instructions.
• Inform your healthcare provider about any side effects you experience, even if they seem mild.
• Do not use Stenocide for any other infections or share it with others, as it is prescribed specifically for your condition.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Common questions about co-amoxiclav (NHS UK) [Accessed 13 Jun. 2024] (online) Available at:
• Augmentin Duo 400/57 powder for oral suspension (mixed fruit flavour) (Health Professionals SmPC) Available at:
• Clavulanic Acid (International database) (Drugs.com) [Accessed 15 Jun. 2024] (online) Available at:
• Amoxicillin and Clavulanic Acid (MedlinePlus) [Accessed 9 Jun. 2024] (online) Available at:
• Keij FM, Kornelisse RF, Hartwig NG, van der Sluijs-Bens J, van Beek RHT, van Driel A, van Rooij LGM, van Dalen-Vink I, Driessen GJA, Kenter S, von Lindern JS, Eijkemans M, Stam-Stigter GM, Qi H, van den Berg MM, Baartmans MGA, van der Meer-Kappelle LH, Meijssen CB, Norbruis OF, Heidema J, van Rossem MC, den Butter PCP, Allegaert K, Reiss IKM, Tramper-Stranders GA. Efficacy and safety of switching from intravenous to oral antibiotics (amoxicillin-clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiority trial. Lancet Child Adolesc Health. 2022 Nov;6(11):799-809. doi: 10.1016/S2352-4642(22)00245-0. Epub 2022 Sep 9. [Accessed 30 Jun. 2024] Available at: